Sprint Bioscience (Sweden) Performance
| SPRINT Stock | SEK 1.82 0.02 1.09% |
On a scale of 0 to 100, Sprint Bioscience holds a performance score of 9. The entity has a beta of -0.24, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Sprint Bioscience are expected to decrease at a much lower rate. During the bear market, Sprint Bioscience is likely to outperform the market. Please check Sprint Bioscience's potential upside, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether Sprint Bioscience's existing price patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Sprint Bioscience AB are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Sprint Bioscience sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 27.1 M | |
| Total Cashflows From Investing Activities | -2.7 M |
Sprint |
Sprint Bioscience Relative Risk vs. Return Landscape
If you would invest 131.00 in Sprint Bioscience AB on September 1, 2024 and sell it today you would earn a total of 51.00 from holding Sprint Bioscience AB or generate 38.93% return on investment over 90 days. Sprint Bioscience AB is generating 0.6183% of daily returns and assumes 4.8869% volatility on return distribution over the 90 days horizon. Simply put, 43% of stocks are less volatile than Sprint, and 88% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Sprint Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sprint Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sprint Bioscience AB, and traders can use it to determine the average amount a Sprint Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1265
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SPRINT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.89 actual daily | 43 57% of assets are more volatile |
Expected Return
| 0.62 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Sprint Bioscience is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sprint Bioscience by adding it to a well-diversified portfolio.
Sprint Bioscience Fundamentals Growth
Sprint Stock prices reflect investors' perceptions of the future prospects and financial health of Sprint Bioscience, and Sprint Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sprint Stock performance.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.59 | |||
| Operating Margin | (76.00) % | |||
| Current Valuation | 24.98 M | |||
| Shares Outstanding | 69.8 M | |||
| Price To Earning | 32.79 X | |||
| Price To Book | 2.61 X | |||
| Price To Sales | 27.09 X | |||
| Revenue | 35.11 M | |||
| EBITDA | (24.22 M) | |||
| Cash And Equivalents | 13.82 M | |||
| Cash Per Share | 1.19 X | |||
| Debt To Equity | 32.20 % | |||
| Book Value Per Share | 0.63 X | |||
| Cash Flow From Operations | (40.12 M) | |||
| Earnings Per Share | (0.75) X | |||
| Total Asset | 79.14 M | |||
| Retained Earnings | (39 M) | |||
| Current Asset | 25 M | |||
| Current Liabilities | 21 M | |||
About Sprint Bioscience Performance
By analyzing Sprint Bioscience's fundamental ratios, stakeholders can gain valuable insights into Sprint Bioscience's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Sprint Bioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sprint Bioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Sprint Bioscience AB develops pharmaceutical products in the areas of cancer and metabolism. Sprint Bioscience AB was founded in 2009 and is based in Huddinge, Sweden. Sprint Bioscience operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.Things to note about Sprint Bioscience performance evaluation
Checking the ongoing alerts about Sprint Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sprint Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sprint Bioscience may become a speculative penny stock | |
| Sprint Bioscience appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 35.11 M. Net Loss for the year was (25.08 M) with profit before overhead, payroll, taxes, and interest of 24.59 M. | |
| Sprint Bioscience AB has accumulated about 13.82 M in cash with (40.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.19. | |
| Roughly 35.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Sprint Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sprint Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Sprint Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sprint Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sprint Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sprint Bioscience's stock. These opinions can provide insight into Sprint Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Sprint Stock analysis
When running Sprint Bioscience's price analysis, check to measure Sprint Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sprint Bioscience is operating at the current time. Most of Sprint Bioscience's value examination focuses on studying past and present price action to predict the probability of Sprint Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sprint Bioscience's price. Additionally, you may evaluate how the addition of Sprint Bioscience to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Global Correlations Find global opportunities by holding instruments from different markets |